PTO/SB/21 (09-04)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

C	Application Number	10/630,206	8		
TRANSMITTAL	Filing Date	JULY 29, 2	29, 2003		
FORM	First Named Inventor	AOKI et al.	•.		
	Art Unit	1656			
(to be used for all correspondence after initial	Examiner Name	KAM, Chih	KAM, Chih Min		
Total Number of Pages in This Submission	11 Attorney Docket Number	Number 17328-CON4(BOT)			
	ENCLOSURES (Check a	ill that apply	á):		
Fee Transmittal Form Fee Attached	Drawing(s) Licensing-related Papers		Appea of App	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences	
Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/	After Final Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Extension of Time Request Request Request Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Document(s) Reply to Missing Parts/		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):		
Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	CUST	OMER NO.			
Firm Name	TORE OF ALTERDARI, ATT	<u> </u>	IX AGENT		
ALLERGAN, INC.					
Signature /CLAUDE L. NASSIF/					
Printed name CLAUDE L. NASSIF					
Date MAY 1, 2007		Reg. No.	52,061		
I hereby certify that this correspondence is be System on the date shown below.	ERTIFICATE OF TRANSMISSED TO TRANSMISSED TO THE PROPERTY OF TRANSMISSED TO THE PROPERTY OF T			ce via the Electronic Filing	
ignature /ADRIANE GIBERSON/					
Typed or printed name: ADRIANE GIBERSON			Date	MAY 1, 2007	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.44. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

App. Ser. No.:10/630,206 Docket: 17328-CON4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kei Roger Aoki et al. | Examiner: KAM Chih Min

Serial Number: 10/630,206 | Art Unit: 1656

Filed: 07/29/2003 | Confirmation No. 1996

For: Treatment of Facial Pain by Irvine, California

Peripheral Administration of a

RESPONSE TO NON-FINAL OFFICE ACTION MAILED FEBRUARY 1, 2007

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Neurotoxin

Dear Sir:

This response to the February 1, 2007 office action amends claims 1, 12, 13 and 31.